Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

63 results
Display

Factors associated with Oncology Nurses' Adherence to Chemotherapy-Induced Neutropenia Guidelines based on Pender's Health Promotion Model

Kim GJ, Choi JY

PURPOSE: This study was conducted to identify factors associated with oncology nurses' adherence to Chemotherapy-Induced Neutropenia (CIN) guidelines based on Pender's Health Promotion Model (HPM). METHODS: For this cross-sectional descriptive study,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study

Kwon WA, Joung JY, Lee JE, Choi SY, Kim SH, Seo HK, Lee KH, Kim CS

PURPOSE: We aimed to evaluate the efficacy and safety of the use of docetaxel plus androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) in Korean patients. MATERIALS AND METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide

Kim GM, Kim JH, Kim JH, Cho YU, Kim SI, Park S, Park HS, Kim JY, Sohn J

PURPOSE: Dose-dense chemotherapy (DD-CT) is a preferred (neo)adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent meta-analysis showed improved overall and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence of Febrile Neutropenia in Advanced Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy in Korea and Its Impact on Prognosis

Park BK, Gwak H, Lim ST, Suh YJ, Jeon YW

PURPOSE: The concurrent regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as a high-risk factor for febrile neutropenia (FN). The incidence of FN was reported to be as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients

Ko JH, Kim SH, Kang CI, Cho SY, Lee NY, Chung DR, Peck KR, Song JH

We implemented a carbapenem-saving strategy in hemato-oncology patients from 2013, using an empirical combination of piperacillin-tazobactam and amikacin for high-risk hemato-oncology patients with febrile neutropenia, who remain hemodynamically unstable >...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Flow-Cytometric Analysis of HNA-2 Expression and Phenotypes Among Thai Blood Donors

Nathalang , Siriphanthong K, Petvises S, Jeumjanya

BACKGROUND: Antibodies specific to human neutrophil antigen (HNA), especially HNA-2, are implicated in various conditions, including neonatal alloimmune neutropenia, febrile non-hemolytic transfusion reactions, and transfusion-related acute lung injury. The distribution...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

Sekiguchi , Hamano A, Kitagawa T, Kurihara Y, Ito K, Kurimoto M, Watanabe K, Hirano K, Noto S, Yamada K, Takezako N

BACKGROUND: Waldenström Macroglobulinemia (WM) is a rare subtype of indolent B-cell lymphoma, and prospective randomized studies on WM are scarce. The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone]...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy

Lee J, Lee JE, Kim Z, Han SW, Hur SM, Kim SY, Lee MH, Lim CW

PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor can effectively prevent febrile neutropenia (FN) during breast cancer treatment. The aims of this study were to evaluate the incidence of FN and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation

Jeon SY, Yhim HY, Kim HS, Kim JA, Yang DH, Kwak JY

BACKGROUND/AIMS: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL) is limited. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Etiology of Bacteremia in Children with Hemato-oncologic Diseases from a Single Center from 2011 to 2015

Park JY, Yun KW, Kang HJ, Park KD, Shin HY, Lee HJ, Choi EH

PURPOSE: The aim of this study was to identify the pathogens of blood stream infection (BSI) in children with hemato-oncologic disorders, to analyze susceptibility patterns of microorganisms to guide empirical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer

Kim M, Keam B, Kim TM, Kim HG, Kim JS, Lee SS, Shin SH, Kim MK, Park KU, Kim DW, Yun HJ, Lee JS, Heo DS

PURPOSE: The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer. MATERIALS AND METHODS: Patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma

Choi EJ, Hong JY, Yoon DH, Kang J, Park CS, Huh J, Chae EJ, Lee Y, Ryu JS, Suh C

BACKGROUND: While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk factors for mortality in patients with bloodstream infections during the pre-engraftment period after hematopoietic stem cell transplantation

Stoma I, Karpov I, Milanovich N, Uss A, Iskrov I

BACKGROUND: Bloodstream infections (BSI) remain a frequent complication during the pre-engraftment period after hematopoietic stem cell transplantation (HSCT), resulting in high mortality rates. This study evaluated risk factors for mortality...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

Yun T, Kim HT, Han JY, Yoon SJ, Kim HY, Nam BH, Lee JS

PURPOSE: Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, Kim IJ, Kim SI, Park S, Park HS, Kim GM

PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Urinary tract infections in pediatric oncology patients with febrile neutropenia

Suh KH, Park SY, Kim SY, Lee JM

BACKGROUND: Neutropenic fever is one of the most common and potentially severe complications of chemotherapy in pediatric oncology patients, while urinary tract infection (UTI) is one of the most prevalent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH, Lee P, Alexandris E, Puri T, Orlando M

PURPOSE: REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis

Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ

PURPOSE: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Although febrile neutropenia (FN) is the major toxicity of this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prophylactic Effect of Pegfilgrastim on Febrile Neutropenia in Patients with Non-Hodgikin's Lymphoma

Jo J, Bang JS

OBJECTIVE: Pegfilgrastim is recently introduced that is long acting G-CSF for prophylaxis of febrile neutropenia. Treatment of non-Hodgikin's lymphoma (NHL) with R-CHOP is classified with relative high risk of febrile...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer

Lee J, Hong TH, Lee IS, You YK, Lee MA

PURPOSE: Gemcitabine-cisplatin combination chemotherapy has been regarded as standard regimen for advanced or metastatic biliary tract cancer (BTC), based on the ABC-02 trial. To date, however, no studies have compared...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr